XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
04 Février 2025 - 1:30PM
XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty
aggregator, announced today members of its Executive Team will
participate at the Oppenheimer 35th Annual Healthcare Life Sciences
Conference being held virtually, February 11-12, 2025.
Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief
Investment Officer, will participate in a fireside chat on Tuesday,
February 11, 2025 at 3:20 PM ET. The presentation can be assessed
by visiting https://bit.ly/4jAMqQw.
XOMA’s presentations can also be accessed by visiting the
investor relations section of the Company’s website at
www.xoma.com. A replay of each presentation will be available
and archived on the site for 90 days after the event.
About XOMA Royalty CorporationXOMA Royalty is a
biotechnology royalty aggregator playing a distinctive role in
helping biotech companies achieve their goal of improving human
health. XOMA Royalty acquires the potential future economics
associated with pre-commercial and commercial therapeutic
candidates that have been licensed to pharmaceutical or
biotechnology companies. When XOMA Royalty acquires the
future economics, the seller receives non-dilutive, non-recourse
funding they can use to advance their internal drug candidate(s) or
for general corporate purposes. The Company has an extensive
and growing portfolio of assets (asset defined as the right to
receive potential future economics associated with the advancement
of an underlying therapeutic candidate). For more information
about the Company and its portfolio, please visit www.xoma.com or
follow XOMA Royalty Corporation on LinkedIn.
XOMA Investor ContactJuliane SnowdenXOMA
Royalty+1 646-438-9754juliane.snowden@xoma.com |
XOMA Media ContactKathy VincentKV Consulting
& Management+1 310-403-8951kathy@kathyvincent.com |
XOMA Royalty (NASDAQ:XOMAO)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
XOMA Royalty (NASDAQ:XOMAO)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025